Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial

Reuters03-24

Context <a href="https://laohu8.com/S/LENZ">Therapeutics</a> targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial

Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.
CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.
CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.
CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.
Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231616PRIMZONEFULLFEED9677071) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621335084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621335084","market":"nz","top_or_hot":-1,"title":"Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.\n        </li>\n<li>\n          CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.\n        </li>\n<li>\n          CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.\n        </li>\n<li>\n          CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231616PRIMZONEFULLFEED9677071) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContext Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 04:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.\n        </li>\n<li>\n          CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.\n        </li>\n<li>\n          CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.\n        </li>\n<li>\n          CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231616PRIMZONEFULLFEED9677071) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2V16.EUR","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLt9lx3:1","article_id":"2621335084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621335084","pubTimestamp":1774297039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","CNTX":"Context Therapeutics Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4007":"制药","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC"},"translate_title":"Context Therapeutics的目标是2026年6月CTIM-76双特异性抗体试验的中期1a期数据","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTX":0.9,"NDAQ":0.9},"content_text":"Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial\n    \n\n\n          Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.\n        \n\n          CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.\n        \n\n          CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.\n        \n\n          CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.\n        \n\n          Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231616PRIMZONEFULLFEED9677071) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621335084","isCrawlerRequest":true}